Reaxys
PubChem
eMolecules
LabNetwork
Reactions (18)
Substances (12)
Structure
Citations (28)
N° of preparations All Preps | All Reactions
Structure/Compound Data Chemical Name: d-modafinil Reaxys Registry Number: 10016759
Type of Substance: isocyclic Molecular Formula: C15H15NO2S Linear Structure Formula: C15H15NO2S Molecular Weight: 273.356
InChI Key: YFGHCGITMMYXAQ-UHFFFAOYSA-N
1 prep out of 1 reactions.
Available Data
N° of ref.
Identification
1
Identification
2
1
Synthesize | Hide Details Find similar Chemical Names and Synonyms d-modafinil, (+)-2-(diphenylmethyl)sulphinylacetamide, (+)-2-(benzhydrylsulphinyl)acetamide, (+)-modafinil Identification Patent-Specific Data (1) Related Markush Structure (RN)
Reference
12205109
CEPHALON FRANCE
Patent: EP1516869 A1, 2005 ; Title/Abstract Full Text Show Details
Chemical Name: l-modafinil Reaxys Registry Number: 10018841
3 prep out of 3 reactions.
Type of Substance: isocyclic Molecular Formula: C15H15NO2S Linear Structure Formula: C15H15NO2S Molecular Weight: 273.356
InChI Key: YFGHCGITMMYXAQ-UHFFFAOYSA-N 2
Synthesize | Hide Details Find similar Chemical Names and Synonyms l-modafinil, (-)-2-(diphenylmethyl)sulphinylacetamide, (-)-benzhydrylsulfinylacetamide, (-)-2-(benzhydrylsulphinyl)acetamide, (-)-modafinil, armodafinil Identification Patent-Specific Data (1) Related Markush Structure (RN)
Reference
12205109
CEPHALON FRANCE
Patent: EP1516869 A1, 2005 ; Title/Abstract Full Text Show Details
Chemical Name: (-)-benzhydrylsulphinylacetamide Reaxys Registry Number: 11334026
Molecular Formula: C15H15NO2S Linear Structure Formula: C15H15NO2S Molecular Weight: 273.356
InChI Key: YFGHCGITMMYXAQ-UHFFFAOYSA-N
4 prep out of 7 reactions.
3
Synthesize | Hide Details Find similar Chemical Names and Synonyms (-)-benzhydrylsulphinylacetamide, l-modafinil, (-)-modafinil, CRL 40982 Physical Data Melting Point (1) Melting Point
Solvent (Melting Point)
Reference
163 °C
ethanol toluene
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Crystal Property Description (1) Colour & Other Properties
Reference
white
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Physical Data (3) Other Data (29)
2
Optical Rotatory Power (1) Type (Optical Rotatory Power)
Solvent (Optical Rotatory Power)
Optical Rotatory Power
Wavelength (Optical Rotatory Power)
[alpha]
methanol
-18.6 deg
589 nm
Reference Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Other Data Use (29) Use Pattern
Reference
promoting CNS stimulation as an adrenergic agonist; activates glutamatergic circuits while inhibiting GABA; inhibits of dopamine reuptake, indirect inhibits of noradrenalin reuptake in the VLPO and orexin activation; has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
promoting or enhancing the state of wakefulness
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
promoting or enhancing the state of alertness
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
central nervous system stimulation
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
excessive daytime sleepiness (EDS)
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
individuals who suffer from narcolepsy
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
promoting a patient's recovery from anesthesia
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
attention deficit disorder (ADD)
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ;
Title/Abstract Full Text Show Details
attention deficit hyperactivity disorder (ADHD)
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
neurorehabilitation program
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
treat an impaired neurological function
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
Parkinson's disease
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
depression, the depressive condition associated with low exposure to sunlight, schizophrenia, rotating shift working, time shifts
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
disturbances of the central nervous system
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
eating disturbances
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
excessive somnolence associated with a disease
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
excessive somnolence associated with narcolepsy
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
excessive somnolence
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
hypersomnia in patients affected by a cancer treated by morphine analgesics to relieve pain
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
idiopathic hypersomnia
Title/Abstract Full Text Show Details
Use Pattern
Reference
narcolepsy
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
obstructive sleep apnoeas
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against alertness disturbances associated with Steinert's disease
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against alertness disturbances, associated with hyperactivity (ADHD)
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against alertness disturbances
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against ischaemia
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
sleep apnoeas
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
somnolence
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
the condition of fatigue, in particular that associated with multiple sclerosis and other degenerative
Cephalon France; Organisation De Synthese Mondiale
Orsymonde
Patent: US2006/135621 A1, 2006 ;
diseases
Title/Abstract Full Text Show Details
Chemical Name: (d)-(+)-modafinil Reaxys Registry Number: 14566857
Molecular Formula: C15H15NO2S Linear Structure Formula: C15H15NO2S Molecular Weight: 273.356
InChI Key: YFGHCGITMMYXAQ-UHFFFAOYSA-N
3 prep out of 3 reactions.
Bioactivity (4) Other Data (29)
4
Synthesize | Hide Details Find similar Chemical Names and Synonyms (d)-(+)-modafinil, (+)-benzhydrylsulphinylacetamide, (+)-modafinil, d-modafinil, CRL 40983 Bioactivity Pharmacological Data (4) 1 of 4
Comment (Pharmacological Data)
Bioactivities present
Reference
CEPHALON FRANCE; ORGANISATION DE SYNTHESE MONDIALE ORSYMONDE
Patent: WO2004/14846 A1, 2004 ; Title/Abstract Full Text Show Details
CENTRE FOR ADDICTION AND MENTAL HEALTH
Patent: WO2006/32146 A1, 2006 ; Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Feuerstein, Seth; Coric, Vladimir
Patent: US2006/167068 A1, 2006 ; Title/Abstract Full Text Show Details
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
BrainCells, Inc.
Patent: US2007/270449 A1, 2007 ; Title/Abstract Full Text Show Details
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2008/21341 A2, 2008 ; Title/Abstract Full Text Show Details
BrainCells, Inc.
Patent: US2008/64671 A1, 2008 ; Title/Abstract Full Text Show Details
Saletu; Frey; Krupka; Anderer; Grunberger; Barbanoj
Arzneimittel-Forschung/Drug Research, 1989 , vol. 39, # 10 p. 1268 - 1273 Title/Abstract Full Text View citing articles Show Details
Ferraro, Luca; Tanganelli, Sergio; O'Connor, William Thomas; Antonelli, Tiziana; Rambert, Francis; Fuxe, Kjell
European Journal of Pharmacology, 1996 , vol. 306, # 1-3 p. 33 - 39 Title/Abstract Full Text View citing articles Show Details
Edgar, Dale M.; Seidel, Wesley F.
Journal of Pharmacology and Experimental Therapeutics, 1997 , vol. 283, # 2 p. 757 - 769 Title/Abstract Full Text View citing articles Show Details
Heitmann, Joerg; Cassel, Werner; Grote, Ludger; Bickel, Ulrich; Hartlaub, Udo; Penzel, Thomas; Peter, Joerg Hermann
Clinical Pharmacology and Therapeutics, 1999 , vol. 65, # 3 p. 328 - 335 Title/Abstract Full Text View citing articles Show Details
Taneja, Indu; Bruehl, Stephen; Robertson, David
25
Journal of Clinical Pharmacology, 2004 , vol. 44, # 12 p. 1425 - 1427 Title/Abstract Full Text View citing articles Show Details
Wong, Y. Nancy; King, S. Peter; Simcoe, Donna; Gorman, Steve; Laughton, Watson; McCormick, George C.; Grebow, Peter
Journal of Clinical Pharmacology, 1999 , vol. 39, # 3 p. 281 - 288 Title/Abstract Full Text View citing articles Show Details
Webb, Ian C.; Pollock, Michael S.; Mistlberger, Ralph E.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 317, # 2 p. 882 - 889 Title/Abstract Full Text View citing articles Show Details
Madras, Bertha K.; Xie, Zhihua; Lin, Zhicheng; Jassen, Amy; Panas, Helen; Lynch, Laurie; Johnson, Ryan; Livni, Eli; Spencer, Thomas J.; Bonab, Ali A.; Miller, Gregory M.; Fischman, Alan J.
Journal of Pharmacology and Experimental Therapeutics, 2006 , vol. 319, # 2 p. 561 - 569 Title/Abstract Full Text View citing articles Show Details
Parmentier; Anaclet; Guhennec; Brousseau; Bricout; Giboulot; Bozyczko-Coyne; Spiegel; Ohtsu; Williams; Lin
Biochemical Pharmacology, 2007 , vol. 73, # 8 p. 1157 - 1171 Title/Abstract Full Text View citing articles Show Details
Dopheide, Marsha M.; Morgan, Russell E.; Rodvelt, Kelli R.; Schachtman, Todd R.; Miller, Dennis K.
European Journal of Pharmacology, 2007 , vol. 568, # 1-3 p. 112 - 123 Title/Abstract Full Text View citing articles Show Details
Ishizuka, Tomoko; Murakami, Masahiro; Yamatodani, Atsushi
European Journal of Pharmacology, 2008 , vol. 578, # 2-3 p. 209 - 215 Title/Abstract Full Text View citing articles Show Details
LAVIN, Thomas, N.
Patent: WO2008/77127 A2, 2008 ; Title/Abstract Full Text Show Details
2 of 4
Comment (Pharmacological Data)
Bioactivities present
Reference
The Board of Trustees of the University of Arkansas
Patent: US2008/221216 A1, 2008 ; Title/Abstract Full Text Show Details
Vincent, Fabien; Nguyen, Margaret T.; Emerling, Daniel E.; Kelly, Michael G.; Duncton, Matthew A.J.
Bioorganic and Medicinal Chemistry Letters, 2009 , vol. 19, # 23 p. 6793 - 6796 Title/Abstract Full Text View citing articles Show Details
Paterson, Neil E.; Fedolak, Allison; Olivier, Berend; Hanania, Taleen; Ghavami, Afshin; Caldarone, Barbara
Pharmacology Biochemistry and Behavior, 2010 , vol. 95, # 4 p. 449 - 456 Title/Abstract Full Text View citing articles Show Details
Dunn, Derek; Hostetler, Greg; Iqbal, Mohamed; Marcy, Val R.; Lin, Yin Guo; Jones, Bruce; Aimone, Lisa D.; Gruner, John; Ator, Mark A.; Bacon, Edward R.; Chatterjee, Sankar
Bioorganic and Medicinal Chemistry Letters, 2012 , vol. 22, # 11 p. 3751 - 3753 Title/Abstract Full Text View citing articles Show Details
Tanganelli; Perez de la Mora; Ferraro; Mendez-Franco; Beani; Rambert; Fuxe
European Journal of Pharmacology, 1995 , vol. 273, # 1-2 p. 63 - 71 Title/Abstract Full Text Show Details
3 of 4
Effect (Pharmacological Data)
wakefulness; effect on
Species or TestSystem (Pharmacological Data)
human
Route of Application
sublingual
Method (Pharmacological Data)
Double blind study of sub-lingual d-modafinil composition in a normal human volunteer.The goal of this test was to confirm the suitability of the sublingual formulation and to ascertain if the purported short acting d-modafinil test article, under conditions of being very tired near to bedtime, had an affect on wakefulness.The test subject was given three vials: one vial containing the base formulation (as in Example 1) to test the taste and delivery means, and two coded vials. One of the coded vials contained 100 mg of d-modafinil formulation, and the second coded vial contained placebo (an equivalent amount of formulation).The subject was instructed to place the contents of the test formulation under the tongue, to allow the formulation to dissolve over two minutes, and to rinse any residual material with some water. ResultsSubject reported that the taste of the base formulation was pronounced, but tolerable. At 11 : 15 p.m. in the evening, the contents of one coded vial was placed under the tongue, allowed to dissolve over two minutes, and any residual was rinsed with some water. A strong taste remained for some time. The test subject then reported reading in bed, dozing on and off for EPO approximately 1.5 hours. After the room was darkened, the subject reported sleeping lighter, and awakening at least once at 3:15 a.m. during the night.On a following evening at 11 : 15 p.m., the contents of the second coded vial was similarly placed under the tongue, allowed to dissolve over two minutes under the tongue and rinsed. The test subject reported reading in bed until 12:50 a.m., then darkening the room and sleeping undisturbed all night until the morning.At both evenings the test subject reported being equally very tired. Approximately one week before these tests, the same subject took 200 mg racemic modafinil (Provigil.(R).) at 10 p.m. and reported a very pronounced effect, essentially being keep awake through the night to 5 a.m. Before unblinding the test articles, the subject recorded that one of the test articles was active, but neither test substance kept him awake as strongly or as long as the 200 mg racemic modafinil. After unblinding the test articles, it was confirmed that the coded vial with the reported activity contained 100 mg d-modafnil.
Results
subject recorded that 100 mg of test compound kept him awake as strongly or as long as the 200 mg racemic modafinil
Location
Page/Page column 20; 21
Reference
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
4 of 4
Effect (Pharmacological Data)
fall asleep; effect on
Route of Application
sublingual
Method (Pharmacological Data)
Double blind crossover study of sub-lingual d-modafinil in normal human volunteers.Two subjects received a set of coded vials containing either 200 mg of d-modafinil formulated according to Example 1 or an equivalent placebo formulation.The subjects were given the following instructions:Start testing at approximately the same time every evening, one hour before bedtime. Randomly select one of the coded vials each day.Open the vials and place the powder under your tongue.Allow the powder to dissolve slowly for approximately 1-2 minutes.After the powder is fully dissolved, you may drink some water.Record observations in a Visual Analogue Scale (VAS) describing the difficulty to fall asleep.Visual Analog Scale (0 to 3)Normal Kept awake, ability to sleep difficult to fall asleep0 1 2 3 0: fell asleep as usual1: slight, noticeable change2: noticeable change3: extreme change (kept awake most of night)Results from Subject 1Observations from vial with code no. 33 (later described as placebo): VAS = 0. No effect noticed. Went to bed at usual time and fell asleep as usual. EPO Observations from the second coded vial (later described as containing 200 mg of d- modafinil): VAS = I. It took longer than usual to fall asleep. Subject awoke several times during the night and felt more awake. Results from Subject 2 Observations from one coded vial (later described as placebo): VAS = 0. No effect noticed. Subject went to bed at usual time and fell asleep as usual.Observations from the second coded vial (later described as containing 200 mg of d- modafinil): VAS = 2. Subject reported that it took longer than usual to fall asleep. Subject reported that he usually falls asleep within a few minutes of reclining, but was significantly more alert after taking the contents of this vial (later revealed as containing 200 mg d-modafinil). After falling asleep, subject awoke several times during the night and after awaking, subject reported that it took a long time to fall asleep again.
Results
in test compound treatment conditions sleep is slight, noticeable change (VAS = 1) or it is noticeable change (VAS = 2); for placebo no effect noticed
Location
Page/Page column 21; 22
Reference
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
Other Data Use (29) Use Pattern
Reference
promoting CNS stimulation as an adrenergic agonist; activates glutamatergic circuits while inhibiting GABA; inhibits of dopamine reuptake, indirect inhibits of noradrenalin reuptake in the VLPO and orexin activation; has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
promoting or enhancing the state of wakefulness
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
promoting or enhancing the state of alertness
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
central nervous system stimulation
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
excessive daytime sleepiness (EDS)
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
individuals who suffer from narcolepsy
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ;
Title/Abstract Full Text Show Details
promoting a patient's recovery from anesthesia
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
attention deficit disorder (ADD)
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
attention deficit hyperactivity disorder (ADHD)
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
neurorehabilitation program
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
treat an impaired neurological function
NEUROHEALING PHARMACEUTICALS, INC.
Patent: WO2007/13962 A2, 2007 ; Title/Abstract Full Text Show Details
Parkinson's disease
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
depression, the depressive condition associated with low exposure to sunlight, schizophrenia, rotating shift working, time shifts
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
disturbances of the central nervous system
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
eating disturbances
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
excessive somnolence associated with a disease
Cephalon France;
Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
excessive somnolence associated with narcolepsy
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
excessive somnolence
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
hypersomnia in patients affected by a cancer treated by morphine analgesics to relieve pain
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
idiopathic hypersomnia
Title/Abstract Full Text Show Details
Use Pattern
Reference
narcolepsy
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
obstructive sleep apnoeas
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against alertness disturbances associated with Steinert's disease
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against alertness disturbances, associated with hyperactivity (ADHD)
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against alertness disturbances
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
protection of the cerebral tissue against ischaemia
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
sleep apnoeas
Title/Abstract Full Text Show Details
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ;
somnolence
Title/Abstract Full Text Show Details
the condition of fatigue, in particular that associated with multiple sclerosis and other degenerative diseases
Cephalon France; Organisation De Synthese Mondiale Orsymonde
Patent: US2006/135621 A1, 2006 ; Title/Abstract Full Text Show Details
Chemical Name: 2-[(R)-(diphenylmethyl)sulfinyl]acetamide hemihydrate Reaxys Registry Number: 15558297
Molecular Formula: C15H15NO2S*0H2O Linear Structure Formula: C15H15NO2S*0.5H2O Molecular Weight: 282.363
InChI Key: TVIKTWOEQIEYMH-FSRHSHDFSA-N
1 prep out of 1 reactions.
Other Data (4)
1
5
Synthesize | Hide Details Find similar Chemical Names and Synonyms 2-[(R)-(diphenylmethyl)sulfinyl]acetamide hemihydrate, Armondafinil hemihydrate Other Data Use (4) Use Pattern
Reference
Excessive sleepiness
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ; Title/Abstract Full Text Show Details
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ;
Excessive sleepiness associated with narcolepsy
Title/Abstract Full Text Show Details
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ;
Shift work sleep disorder ("SWSD")
Title/Abstract Full Text Show Details
Obstructive sleep apnea/hypopnea syndrome ("OSA/HS")
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ; Title/Abstract Full Text Show Details
Chemical Name: 2-[(R)-(diphenylmethyl)sulfinyl]acetamide monohydrate Reaxys Registry Number: 15558295
CAS Registry Number: 947318-12-9 Molecular Formula: C15H15NO2S*H2O
1 prep out of 1 reactions.
Other Data (4)
1
Linear Structure Formula: C15H15NO2S*H2O Molecular Weight: 291.371
InChI Key: TVIKTWOEQIEYMH-FSRHSHDFSA-N 6
Synthesize | Hide Details Find similar Chemical Names and Synonyms 2-[(R)-(diphenylmethyl)sulfinyl]acetamide monohydrate, Armondafinil monohydrate Other Data Use (4) Use Pattern
Reference
Excessive sleepiness
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ; Title/Abstract Full Text Show Details
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ;
Excessive sleepiness associated with narcolepsy
Title/Abstract Full Text Show Details
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ;
Shift work sleep disorder ("SWSD")
Title/Abstract Full Text Show Details
Obstructive sleep apnea/hypopnea syndrome ("OSA/HS")
TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patent: WO2007/98273 A2, 2007 ; Title/Abstract Full Text Show Details
Chemical Name: (-)-modafinil acetonitrile solvate Reaxys Registry Number: 14566865
Molecular Formula: C2H3N*C15H15NO2S Linear Structure Formula: C2H3N*C15H15NO2S Molecular Weight: 314.408
InChI Key: JCXVRAJKQXEWHI-UHFFFAOYSA-N
1 prep out of 2 reactions.
1
1 prep out of 2 reactions.
1
7
Synthesize | Hide Details Find similar Chemical Names and Synonyms (-)-modafinil acetonitrile solvate Chemical Name: (+)-modafinil acetonitrile solvate Reaxys Registry Number: 14566866
Molecular Formula: C H N*C H NO S
2 3
8
15 15
2
Linear Structure Formula: C2H3N*C15H15NO2S Molecular Weight: 314.408
InChI Key: JCXVRAJKQXEWHI-UHFFFAOYSA-N
Synthesize | Hide Details Find similar Chemical Names and Synonyms (+)-modafinil acetonitrile solvate Chemical Name: (-)-modafinil acetic acid solvate
9
Reaxys Registry Number: 14566867
Molecular Formula: C2H4O2*C15H15NO2S Linear Structure Formula: C2H4O2*C15H15NO2S Molecular Weight: 333.408
InChI Key: JIQSCEZLYJHZBC-UHFFFAOYSA-N
1 prep out of 2 reactions.
1
1 prep out of 1 reactions.
1
1 prep out of 2 reactions.
1
Synthesize | Hide Details Find similar Chemical Names and Synonyms (-)-modafinil acetic acid solvate Chemical Name: (+)-modafinil acetic acid solvate Reaxys Registry Number: 14566868
Molecular Formula: C2H4O2*C15H15NO2S Linear Structure Formula: C2H4O2*C15H15NO2S Molecular Weight: 333.408
InChI Key: JIQSCEZLYJHZBC-UHFFFAOYSA-N
10
Synthesize | Hide Details Find similar Chemical Names and Synonyms (+)-modafinil acetic acid solvate Chemical Name: (-)-modafinil dimethylcarbonate solvate Reaxys Registry Number: 14566869
Molecular Formula: C3H6O3*C15H15NO2S Linear Structure Formula: C3H6O3*C15H15NO2S Molecular Weight: 363.434
InChI Key: QAPFKNAFCAMEED-UHFFFAOYSA-N
11
Synthesize | Hide Details Find similar Chemical Names and Synonyms (-)-modafinil dimethylcarbonate solvate, monodimethyl carbonate solvate of (-)-modafinil Chemical Name: (+)-modafinil dimethylcarbonate solvate Reaxys Registry Number: 14566870
Molecular Formula: C3H6O3*C15H15NO2S Linear Structure Formula: C3H6O3*C15H15NO2S Molecular Weight: 363.434
InChI Key: QAPFKNAFCAMEED-UHFFFAOYSA-N 12
Synthesize | Hide Details Find similar Chemical Names and Synonyms (+)-modafinil dimethylcarbonate solvate
1 prep out of 2 reactions.
1